Systematic Review and Network Meta-Analysis Compares Enteral Nutrition and Medications in Pediatric Crohn's Disease
Photo by Growtika / Unsplash
Key Takeaway
Consider enteral nutrition for induction in pediatric Crohn's disease; evidence shows superiority over corticosteroids.
This systematic review and network meta-analysis synthesized data from 1,182 patients with pediatric Crohn's disease to compare enteral nutrition strategies against immunomodulators and corticosteroids. The authors evaluated clinical remission induction, mucosal healing, and maintenance outcomes across various nutritional and pharmacological interventions within the pediatric population.
Regarding induction, exclusive enteral nutrition was significantly superior to corticosteroids for clinical remission with an odds ratio of 1.72 (95% CI 1.18–2.52). For mucosal healing, exclusive enteral nutrition demonstrated marked superiority versus corticosteroids with an odds ratio of 7.55 (95% CI 3.59-15.88). SUCRA rankings placed CDED plus PEN at 0.80 and exclusive enteral nutrition at 0.78 for remission induction, while corticosteroids ranked lowest at 0.31.
Safety data indicated serious adverse events ranged from 0%–3.1% for enteral nutrition therapies compared to 15.1% for corticosteroids and 11.8% for azathioprine or 6-mercaptopurine. Notably, these safety profiles differ between nutritional and pharmacological approaches. For maintenance, azathioprine or 6-mercaptopurine was superior to placebo with an odds ratio of 12.50 (95% CI 2.47–63.14).
The authors note that these findings support enteral nutrition as first-line induction therapy in pediatric Crohn's disease. However, the review does not report follow-up duration or absolute numbers for all outcomes. Clinicians should interpret these pooled estimates within the context of available evidence and individual patient factors carefully.
More on Crohn's Disease
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Guselkumab shows promise for ulcerative colitis in this early phase 3 trial.
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
Clinical features and treatment responses in 40 male patients with VEXAS syndrome
HMA treatment shows promise for VEXAS syndrome patients
This retrospective multicenter study of 40 male patients with VEXAS syndrome evaluated clinical features and various treatment responses. Re…
New data on VEXAS syndrome suggests that hypomethylating agents may help improve clinical and biological responses in men.
Meta-analysis shows reduced oral microbial Shannon diversity in Crohn's disease versus controls
Oral bacteria shifts could reveal Crohn's disease risk
This meta-analysis reviews data from multiple cohorts involving 1,136 IBD patients and 759 controls. The authors synthesize findings on oral…
A new study links distinct mouth bacteria changes to higher gut inflammation levels in Crohn's disease patients.
View Original Abstract ↓
BackgroundEnteral nutrition (EN) and immunomodulators are established therapies for pediatric Crohn's disease (CD), yet comparative effectiveness data remain limited.ObjectiveWe conducted a network meta-analysis (NMA) to compare the efficacy and safety of EN therapies vs. immunomodulators and corticosteroids for remission induction and maintenance in pediatric CD.MethodsWe systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science from inception through October 2024. Randomized controlled trials (RCTs) and comparative observational studies evaluating exclusive enteral nutrition (EEN), partial enteral nutrition (PEN), Crohn's Disease Exclusion Diet plus PEN (CDED + PEN), supplemental enteral nutrition (SEN), corticosteroids (CS), azathioprine/6-mercaptopurine (AZA/6-MP), or methotrexate (MTX) were included. Primary outcomes were clinical remission and mucosal healing. Frequentist NMA was performed using random-effects models. Surface under the cumulative ranking curve (SUCRA) values determined treatment rankings.ResultsTwenty studies (7 RCTs, 13 observational) comprising 1,182 patients were included. For clinical remission induction, EEN was significantly superior to CS [odds ratio [OR] 1.72; 95% confidence interval [CI] 1.18–2.52; 7 studies; I2 = 0%]. EEN demonstrated marked superiority for mucosal healing vs. CS (OR 7.55; 95% CI 3.59-15.88). SUCRA rankings for remission induction were: CDED + PEN (0.80), EEN (0.78), MTX (0.55), AZA/6-MP (0.47), CS (0.31), and PEN (0.08). For maintenance, AZA/6-MP was superior to placebo (OR 12.50; 95% CI 2.47–63.14). EN therapies exhibited favorable safety profiles with serious adverse event rates of 0%–3.1% compared with 15.1% for CS and 11.8% for AZA/6-MP.ConclusionsEEN and CDED + PEN are the most effective treatments for inducing clinical and endoscopic remission in pediatric CD, with superior safety profiles compared to pharmacological therapies. Immunomodulators remain essential for maintenance therapy. These findings support EN as first-line induction therapy in pediatric CD.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261345561, PROSPERO CRD420261345561.
Standardized formal resuscitation training likely reduces neonatal mortality in low- and middle-income countries compared to no training or basic training.
A Simple Training Program Is Saving Newborn Lives in Poor Countries
Related in Pediatrics
Therapeutic Touch Reduces Crying and Improves Sleep in Infants With Colic
Therapeutic touch reduces crying in babies with colic
This randomized controlled trial in 96 infants with colic found that therapeutic touch based on Watson's Human Care Theory significantly red…
A new trial shows gentle therapeutic touch helps babies cry less and sleep better when they have infantile colic.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
AquOTic water competency intervention improves outcomes in children with autism
Water therapy improves skills for children with autism spectrum disorder
This pre-post cohort study of 37 children with autism ages 5 to 9 found that a 10-week occupational therapy-based water competency intervent…
A water-based occupational therapy program significantly improved performance and satisfaction scores in children with autism spectrum disor…
Play-based cognitive flexibility training boosts creativity in third graders
Playful workshops boost story skills and flexible thinking for third graders
This RCT in 249 third graders found that a 14-session play-based workshop significantly improved narrative creativity and cognitive flexibil…
A fun 14-session workshop helped third graders write better stories and think more flexibly than peers in regular classes.
From Other Specialties
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not